Inclusion Body Myositis
29
3
6
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.4%
1 terminated out of 29 trials
94.1%
+7.6% vs benchmark
10%
3 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (29)
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
Environmental Risk Factors for Myositis in Military Personnel
Adult and Juvenile Myositis
IBM Dietary Surveillance Study
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Sporadic Inclusion Body Myositis Natural History Study
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Phase III Trial of Sirolimus in IBM
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
The Risk of Falls Index for Patients With Neuromuscular Disorders
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Cell Therapy for IBM by Muscle Injection of ADSVF